Tejpar, Sabine

Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer

Yan, P., Klingbiel, D., Saridaki, Z., Ceppa, P., Curto, M., McKee, T. A., Roth, A., Tejpar, S., Delorenzi, M., Bosman, F. T., et al. (2016) · Clinical Cancer Research

Genetic factors in colorectal cancerTGF-β signaling in diseases

Cited by 78

Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer

Borràs, D. M., Verbandt, S., Ausserhofer, M., Sturm, G., Lim, J., Verge, G. A., Vanmeerbeek, I., Laureano, R. S., Govaerts, J., Sprooten, J., et al. (2023) · Cell Discovery

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 67

Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients

Ciardiello, F., Adams, R., Tabernero, J., Seufferlein, T., Taieb, J., Moiseyenko, V., Ma, B., Lopez, G., Vansteenkiste, J. F., Esser, R., et al. (2016) · The Oncologist

Patient-Provider Communication in HealthcareCancer Genomics and Diagnostics

Cited by 53

BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer

Ramesh, P., Lannagan, T. R. M., Jackstadt, R., Atencia Taboada, L., Lansu, N., Wirapati, P., van Hooff, S. R., Dekker, D., Pritchard, J., Kirov, A. B., et al. (2021) · Cell Death & Differentiation

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 52

Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity

Wirapati, P., Pomella, V., Vandenbosch, B., Kerr, P., Maiello, E., Jeffery Grahame, M., Curca, R.-O. D., Karthaus, M., Bridgewater, J. A., Mihailov, A. C., et al. (2017) · Annals of Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 39

The Prognostic Role of Ephrin A2 and Endothelial Growth Factor Receptor Pathway Mediators in Patients With Advanced Colorectal Cancer Treated With Cetuximab

Strimpakos, A., Pentheroudakis, G., Kotoula, V., De Roock, W., Kouvatseas, G., Papakostas, P., Makatsoris, T., Papamichael, D., Andreadou, A., Sgouros, J., et al. (2013) · Clinical Colorectal Cancer

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 27

Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial

Teufel, M., Schwenke, S., Seidel, H., Beckmann, G., Reischl, J., Vonk, R., Lenz, H.-J., Tabernero, J., Siena, S., Grothey, A., et al. (2015) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 26

Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer

Corry, S. M., McCorry, A. M., Lannagan, T. R., Leonard, N. A., Fisher, N. C., Byrne, R. M., Tsantoulis, P., Cortes-Lavaud, X., Amirkhah, R., Redmond, K. L., et al. (2022) · Gut

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 18

Awareness and Understanding of Stratified/Personalized Medicine in Patients Treated for Cancer: A Multinational Survey

Tejpar, S., Teague, T., Lake, J., Tabernero, J., Vansteenkiste, J. F., Vlassak, S., & Ciardiello, F. (2012) · Annals of Oncology

Patient-Provider Communication in HealthcareBRCA gene mutations in cancer

Cited by 2